Pharma-Bio Serv, Inc. Form 8-K December 19, 2014

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT PURSUANT TO SECTION 13 or 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

Date of report (Date of earliest event reported): December 15, 2014

Pharma-Bio Serv, Inc. (Exact Name of Registrant as Specified in Its Charter)

Delaware (State or Other Jurisdiction of Incorporation)

0-50956 20-0653570 (Commission File Number) (I.R.S. Employer Identification No.)

6 Road 696, Dorado, Puerto Rico 00646 (Address of Principal Executive Offices) (Zip Code)

(787) 278-2709 (Registrant's Telephone Number, Including Area Code)

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Edgar Filing: Pharma-Bio Serv, Inc. - Form 8-K

Item Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; 5.02. Compensatory Arrangements of Certain Officers.

The Compensation Committee of the Board of Directors of Pharma-Bio Serv, Inc. accelerated the vesting of options to purchase 66,600 shares of common stock of the Company at an exercise price of \$0.72 per share previously granted to Nelida Plaza and, pursuant to the terms of Ms. Plaza's employment agreement, approved a bonus of \$45,000 (representing 20% of Ms. Plaza's base salary) for the year ended October 31, 2014.

2

Edgar Filing: Pharma-Bio Serv, Inc. - Form 8-K

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

PHARMA-BIO SERV, INC.

Date: December 19, 2014 By: /s/ Pedro J. Lasanta

Chief Financial Officer and Vice President

Finance and Administration

3